| Number of compounds |
1,040 |
| Plate Numbers |
0500-0503 (4 Plates) |
| Concentration Information |
10 mM in DMSO |
| Plate Format |
384-well Plate
Plates 500-502:
Columns 1-2 and 23-24 (empty)
 Click plate image to enlarge
Plate 503:
Partial plate, see details below
 Click plate image to enlarge
|
This collection of characterized bioactive compounds was compiled
by MicroSource Discovery Systems
for the National Institute of Neurological Disorders and Stroke
(NINDS), the Huntington’s
Disease Society of America
(HDSA), the Amyotrophic Lateral
Sclerosis (ALS) Association,
and the Hereditary Disease Foundation (HDF).
It was purchased in December, 2001 by the ALS Association via ICCB-Longwood
post-doctoral fellow Qing Liu. Three quarters of the compounds
in the collection are FDA-approved and the rest - which include
some controlled substances such as cannabinoids - are known to influence
brain activity.
Investigators wishing to screen the maximum number of FDA-approved drugs can achieve ~46% coverage (561 compounds) of the FDA set by screening both NINDS and Prestwick. Including the ICCB Biomol Known Bioactives will increase coverage to ~47% of the FDA set, as there is some redundancy among these three libraries
Click here
to view a complete list of the compounds in this collection.
For chemical structures and more information about each compound,
please go to the ICCB-Longwood Screensaver site.
|
